<DOC>
	<DOCNO>NCT00062270</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Biological therapy gefitinib may interfere growth tumor cell slow growth tumor . Combining chemotherapy radiation therapy gefitinib surgery may shrink tumor remove surgery . PURPOSE : Phase I/II trial compare effectiveness neoadjuvant chemoradiotherapy without gefitinib treat patient undergo surgery stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Neoadjuvant Chemoradiotherapy With Without Gefitinib Treating Patients With Stage IIIA Stage IIIB Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Phase I : - Determine tolerability toxicity gefitinib combination chest radiotherapy patient stage IIIA stage IIIB non-small cell lung cancer . Phase II : - Compare pathologic response ( complete response rate downstaging ) patient treat neoadjuvant chemoradiotherapy v without gefitinib . - Compare feasibility toxicity profile regimens patient . - Compare resection rate , time progression , overall survival patient treat regimen . - Correlate percent decline fludeoxyglucose F 18 standardize uptake value measure position emission tomography pathologic response resection , time progression , overall survival patient treat regimen . OUTLINE : - Phase I : This open-label , nonrandomized study . - Induction : Patients receive cisplatin IV 60 minute day 1 gemcitabine IV 30 minute day 1 8 . Treatment repeat every 3 week total 2 course absence disease progression unacceptable toxicity . - Consolidation : Within 3-4 week completion induction therapy , patient undergo radiotherapy daily 5 day week 5 week receive oral gefitinib daily concurrently . A cohort 3-6 patient receive consolidation chemoradiotherapy . If 2 6 patient experience dose-limiting toxicity , gefitinib delete consolidation therapy phase II arm II . - Surgery : Patients without disease progression consolidation therapy undergo thoracotomy within 3-5 week consolidation . - Maintenance : Beginning 2-4 week surgery , patient receive oral gefitinib daily 6 month absence disease progression . - Phase II : This randomize study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive induction consolidation therapy ( exception gefitinib ) phase I . Patients also receive docetaxel IV 60 minute concurrently radiotherapy consolidation . Patients undergo surgery phase I . - Arm II : Patients receive therapy ( include gefitinib ) phase I . Patients also receive docetaxel IV 60 minute concurrently radiotherapy consolidation . Patients follow every 6-8 week first 12 month every 4-6 month thereafter . PROJECTED ACCRUAL : A total 43-80 patient ( 3-6 patient phase I 40-74 patient [ 20-37 per treatment arm ] phase II ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Stage IIIA ( T13 , N2 ) Positive ( pathological ) ipsilateral mediastinal node Selective stage IIIB meeting follow criterion : No pleural/pericardial effusion superior vena cava syndrome T4 due invasion carina , trachea , mediastinal structure Mediastinal N3 node ( without supraclavicular cervical adenopathy ) Proof N2 N3 status require surgical stag mediastinum ( mediastinoscopy , mediastinotomy , exploration ) Expression epidermal growth factor receptor ( least 1+ ) immunohistochemistry Measurable disease contrast CT scan allow No bronchoalveolar cell carcinoma No prior diagnosis lung cancer PATIENT CHARACTERISTICS : Age 19 Performance status ECOG 01 ( 02 albumin least 0.85 time low limit normal weight loss within 3 month diagnosis great 10 % ) Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 150,000/mm^3 Hemoglobin least 10 g/dL Hepatic Bilirubin normal AST ALT great 2.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN Alkaline phosphatase 1.52 time ULN require negative bone scan metastatic bone disease Renal Creatinine great 1.4 mg/dL OR Creatinine clearance least 60 mL/min Cardiac No myocardial infarction within past 3 month No active angina No unstable heart rhythms No congestive heart failure Pulmonary Postresection predict FEV_1 % great 35 % Predicted FEV_1 % define FEV_1 % time percent perfusion uninvolved lung quantitative lung V/Q scan report Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 6 week study treatment No uncontrolled medical illness No malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix No grade 2 great peripheral neuropathy No concurrent ocular inflammation infection No prior severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 No know severe hypersensitivity reaction gefitinib excipients No prior severe allergic reaction platinumcontaining compound mannitol PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent growth factor ( e.g. , filgrastim [ GCSF ] sargramostim [ GMCSF ] ) chemotherapy Chemotherapy No prior chemotherapy lung cancer Endocrine therapy Not specify Radiotherapy No prior radiotherapy lung cancer Surgery Recovered prior major surgery No concurrent ophthalmic surgery Other More 30 day since prior unapproved investigational drug No concurrent use follow drug : Phenytoin Carbamazepine Barbiturates Rifampin Phenobarbital Hypericum perforatum ( St. John 's Wort ) Warfarin No concurrent retinoids</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>